Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA

seekingalpha08-10

The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458547725?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/508919350/image_508919350.jpg","is_english":true,"pubTime":"2024-08-10 06:04","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2458547725","market":"hk","top_or_hot":-1,"title":"Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA","media":"seekingalpha","content":"<div>\n<p>The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising ...</p>\n\n<a href=\"https://seekingalpha.com/news/4138378-psychedlic-drug-developers-setback-ecstasy-based-drug-rejected-fda\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Psychedelic drug developers face setback as ecstasy-based drug rejected by FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPsychedelic drug developers face setback as ecstasy-based drug rejected by FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-10 06:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4138378-psychedlic-drug-developers-setback-ecstasy-based-drug-rejected-fda><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising ...</p>\n\n<a href=\"https://seekingalpha.com/news/4138378-psychedlic-drug-developers-setback-ecstasy-based-drug-rejected-fda\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SQQQ","symbol_name":"纳指三倍做空ETF","start_time":0,"source_url":"https://seekingalpha.com/news/4138378-psychedlic-drug-developers-setback-ecstasy-based-drug-rejected-fda","article_id":"2458547725","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/508919350/image_508919350.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458547725","pubTimestamp":1723241074,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising con","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SQQQ":"纳指三倍做空ETF",".IXIC":"NASDAQ Composite","BK4547":"WSB热门概念","DRUG":"Bright Minds Biosciences Inc","ATAI":"ATAI Life Sciences B.V.*","GHRS":"GH Research PLC","SPRC":"SciSparc Ltd.","QID":"纳指两倍做空ETF","TQQQ":"纳指三倍做多ETF","CMND":"Clearmind Medicine, Inc.","BK4539":"次新股","MNMD":"Mind Medicine (MindMed) Inc.","ATNF":"180 Life Sciences Corp","BK4139":"生物科技","PSQ":"纳指反向ETF","BK4007":"制药","ENVB":"Enveric Biosciences","CMPS":"COMPASS Pathways plc","QLD":"纳指两倍做多ETF","SEEL":"Seelos Therapeutics Inc."},"translate_title":"迷幻药开发商因摇头丸药物被FDA拒绝而面临挫折","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATAI":1,"ATNF":1,"SPRC":1,"SEEL":1,"CMND":1,"CMPS":1,"DRUG":1,"ENVB":1,"GHRS":1,"MNMD":1,".IXIC":0.9,"TQQQ":0.6,"SQQQ":0.6,"QLD":0.6,"QID":0.6,"PSQ":0.6,"NQmain":0.6,"MNQmain":0.6},"content_text":"The U.S. FDA has rejected privately-held Lykos Therapeutics' drug related to the psychedelic MDMA, also known as ecstasy, for PTSD. The issuing of a Complete Response Letter is not that surprising considering an agency advisory committee in June did not endorse the idea that the benefits of the drug outweigh the risk or that the drug was effective.  Although FDA briefing documents provided for the meeting said that studies indicated the MDMA treatment led to rapid and durable improvement in symptoms, scientists also expressed concerns about cardiac safety. In addition, they worried how given the effects MDMA has on mood and cognition, they questioned how studies could be truly blinded. Publicly traded psychedelic-focused drug developers include Mind Medicine (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI), COMPASS Pathways (NASDAQ:CMPS), Cybin (NYSE:CYBN), and GH Research (GHRS). Nano-caps include 180 Life Sciences (ATNF), Enveric Biosciences (ENVB), Seelos Therapeutics (NASDAQ:NASDAQ:SEEL), SciSparc (SPRC), Bright Minds Biosciences (DRUG), and Clearmind Medicine (CMND).   More on psychedelic drug developers  MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy Compass Pathways: Buy It For Its Promising Psychedelic Mental Health Therapies Mind Medicine prices $75M securities offering Mind Medicine stock dips on proposed securities offering COMPASS Pathways plc (CMPS) Q2 2024 Earnings Call Transcript","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"Policy And Regulatory","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458547725"}